Septin-5 Polypeptide Detection and Depletion for Autoimmune Ataxia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods are inadequate for effectively detecting and treating autoimmune ataxias associated with septin-specific autoantibodies, such as septin-5-specific autoantibodies, which contribute to cerebellar degeneration and related disabilities.
Innovation Solution
The use of septin-5 polypeptides to detect the presence of septin-5-specific autoantibodies in biological samples and treat autoimmune ataxias by forming complexes with these antibodies, allowing for their removal from biological fluids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional detection methods are used for autoimmune ataxias, then general screening is possible, but detection precision for septin-5-specific autoantibodies is insufficient
Solution Approach 1:
The patent segments the detection process by using specific septin-5 polypeptide fragments (containing epitopes recognized by autoantibodies) rather than whole proteins. This segmentation allows for more precise detection of septin-5-specific autoantibodies while simplifying the detection system through focused use of specific antigenic regions.
Solution Approach 2:
The patent introduces septin-5 polypeptides as intermediary substances that specifically bind to septin-5-specific autoantibodies in patient samples. These polypeptides act as mediators between the autoantibodies and detection systems, enabling precise identification of the autoimmune condition through specific antigen-antibody interactions.
2Reliability
If septin-5-specific autoantibodies are not specifically targeted, then general autoimmune screening is simpler, but treatment effectiveness for autoimmune ataxia is reduced
Solution Approach 1:
The patent applies local quality by using specific septin-5 polypeptide regions (epitopes) that are locally recognized by pathogenic autoantibodies. This localized approach ensures that treatment targets specifically the harmful autoantibodies associated with autoimmune ataxia rather than applying generalized treatments, thereby improving effectiveness while maintaining manageable complexity.
Solution Approach 2:
The patent changes the parameter of antigen specificity by using defined septin-5 polypeptide sequences with specific epitopes. This parameter change from general autoimmune markers to specific septin-5 epitopes enables reliable identification and treatment of septin-5-specific autoimmune ataxia, improving treatment reliability through precise molecular targeting.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables accurate diagnosis and treatment of autoimmune ataxias by identifying and depleting septin-5-specific autoantibodies, potentially reducing symptoms and improving patient outcomes.
Implementation Method 1
contacting a biological sample from a mammal with a septin-5 polypeptide to form a septin-5/septin-5-specific autoantibody complex if the biological sample contains septin-5-specific autoantibodies
Data Source
AI summary
Methods and materials herein are useful for assessing and/or treating autoimmune ataxias associated with septin-specific autoantibodies (e.g., septin-5-specific autoantibodies). For example, septin-5 polypeptides are provided as well as methods for using septin-5 polypeptides to detect septin-5-specific autoantibodies and/or to treat a mammal having an autoimmune ataxia.